Liven Pharma Limited (PSX:LIVEN)
Pakistan · Delayed Price · Currency is PKR 31.48
-0.42 (-1.32%)
At close: Oct 19, 2026
Liven Pharma Ratios and Metrics
Market cap in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 3,559 | 4,603 | 6,042 | 110 | 185 | 152 | |
Market Cap Growth | -39.72% | -23.82% | 5370.54% | -40.46% | 21.91% | -49.80% |
Enterprise Value | 3,410 | 4,452 | 6,080 | 349 | 423 | 387 |
Last Close Price | 31.79 | 40.72 | 55.17 | 7.74 | 13.00 | 10.66 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | - | - | - | 2.65 | - | - |
PS Ratio | 33.96 | 43.50 | 47.47 | 0.45 | - | - |
PB Ratio | 3.65 | 4.67 | 9.53 | 0.15 | -1.51 | -1.38 |
P/TBV Ratio | 3.66 | 4.69 | 9.66 | 0.15 | - | - |
P/FCF Ratio | - | - | - | 8.00 | - | - |
P/OCF Ratio | 399.93 | 512.27 | - | 8.00 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 32.56 | 42.07 | 47.77 | 1.42 | - | - |
EV/EBITDA Ratio | - | - | - | 5.37 | - | - |
EV/EBIT Ratio | - | - | - | 8.35 | - | - |
EV/FCF Ratio | - | - | - | 25.26 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.06 | 0.21 | -1.94 | -2.13 |
Debt / EBITDA Ratio | - | - | - | 2.35 | - | - |
Debt / FCF Ratio | - | - | - | 11.37 | - | - |
Net Debt / Equity Ratio | -0.15 | -0.15 | 0.04 | 0.18 | -1.94 | -2.13 |
Net Debt / EBITDA Ratio | 3.19 | 3.19 | -0.06 | 2.03 | -111.87 | -79.65 |
Net Debt / FCF Ratio | 7.16 | 7.16 | -1.09 | 9.56 | -104.83 | -104.11 |
Asset Turnover | 0.10 | 0.10 | 0.14 | 0.46 | - | - |
Inventory Turnover | 1.08 | 1.08 | 0.90 | - | - | - |
Quick Ratio | 1.74 | 1.74 | 0.19 | 0.71 | 0 | 0 |
Current Ratio | 2.63 | 2.63 | 1.64 | 1.48 | 0 | 0 |
Return on Equity (ROE) | -3.85% | -3.85% | -84.49% | 13.31% | - | - |
Return on Assets (ROA) | -4.66% | -4.66% | -35.12% | 4.93% | -6.89% | -7.20% |
Return on Capital Employed (ROCE) | -6.90% | -6.90% | -67.10% | 5.60% | 14.20% | 19.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | -0.87% | -0.68% | -9.67% | 37.80% | -6.65% | -9.39% |
FCF Yield | -0.58% | -0.45% | -0.41% | 12.50% | -1.22% | -1.49% |
Buyback Yield / Dilution | -35.87% | -35.87% | -205288.50% | 99.67% | - | - |